1. What Is the RSV Vaccine Market?
The RSV Vaccine Market covers the prophylactic vaccines and monoclonal antibody prophylactics targeting the respiratory syncytial virus. RSV is the leading cause of infant hospitalisation in high-income countries and a major cause of childhood lower respiratory tract disease mortality in low-income countries. RSV is also the leading cause of respiratory hospitalisation in adults over 60, making it a priority pathogen for both paediatric and adult vaccine development. The RSV vaccine market represents over 60 years of vaccine development effort following the failed 1960s formalin-inactivated RSV vaccine that caused vaccine-enhanced disease in seronegative infants. The breakthrough prefusion F protein stabilisation identified the neutralising epitopes accessible only on the prefusion conformation as the key antigen design approach. Protective immunity was achieved without the vaccine-enhanced disease that the postfusion F antigen failed to avoid. Multiple approved RSV preventive products including protein subunit vaccines for adults over 60 and a maternal RSV vaccine protecting infants through the transferred maternal antibody launched in 2023. A long-acting monoclonal antibody for infant RSV prevention also received approval and deployment that year. National recommendations for RSV vaccines in adults 60 and older, the maternal RSV vaccine programme, and the infant monoclonal antibody administration programme represent the RSV prevention landscape. This represents the transformation from the 60-year development failure into the multiple approved products of 2023.
2. RSV Vaccine Market Size & Forecast
3. Emerging Technologies
- Prefusion F protein conformation stabilisation using the disulphide bonds and cavity-filling mutations that Jason McLellan and colleagues introduced into the RSV prefusion F protein prevented its spontaneous conversion to the postfusion conformation during manufacturing. The stabilised prefusion F antigen enabled the first RSV vaccines to successfully elicit the broadly neutralising antibodies that the prefusion epitopes present to the immune system. The postfusion antigen that previous vaccine candidates used could not generate these antibodies at the titre that RSV protection requires.
- Maternal RSV vaccine efficacy in the MATISSE Phase III trial demonstrated 82 percent protection against RSV lower respiratory tract disease with oxygen requirement in infants during the first 90 days of life. The maternal antibody is transferred across the placenta during the third trimester of the vaccinated mother's pregnancy. This maternal immunisation strategy protects the youngest and most vulnerable infants who are too young to mount their own vaccine-induced immune response.
- Nirsevimab Beyfortus single-dose monoclonal antibody protects infants for the entire RSV season from the extended half-life that the YTE Fc modification provides. The monthly palivizumab injections that prior prophylaxis required for the same season-long protection have been replaced by the single dose at birth or season entry. The administration burden for the high-risk infant is reduced from 5 monthly injections to the single nirsevimab dose.
- Adult RSV vaccine market dynamics in the adults 60 and older segment are being determined by the healthcare provider recommendation and the formulary placement. Shared clinical decision-making guidance that national advisory committees issue for the product choice is the key access mechanism. Both protein subunit vaccines demonstrated comparable efficacy against RSV lower respiratory tract disease in their pivotal trials. The competitive market between the two approved products has driven pricing and access discussions at the payer and health system level.
Similar technologies are also transforming adjacent markets. Learn more in our Flu Vaccine Market.
4. Key Market Opportunity
Material revenue potential in the RSV Vaccine market is market penetration among eligible elderly adults, where initial uptake from the large adult-over-60 population eligible for RSV vaccination has barely begun relative to the total addressable population. Manufacturers and healthcare systems increasing RSV awareness and access capture this penetration opportunity. Additional momentum is centered on combination mRNA respiratory vaccines including RSV. As elderly RSV vaccination penetration grows and mRNA RSV programmes advance, the addressable opportunity is scaling from early commercial launch toward broad annual respiratory immunisation.
5. Top Companies in the RSV Vaccine Market
The following organisations hold leading positions in the RSV Vaccine Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Pfizer
- GSK
- Moderna
- Sanofi
- AstraZeneca
- Bavarian Nordic
- Johnson and Johnson
- Novavax
6. Market Segmentation
The RSV Vaccine Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Product Type | Protein SubunitmRNA |
| By Target | Elderly AdultMaternalPaediatric |
| By Distribution | Commercial Private PayGovernment Procurement |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the RSV Vaccine Market trajectory over the forecast period:
Prefusion F Protein Stabilisation by McLellan and Colleagues Enabling Broadly Neutralising Antibody Induction Against the Native RSV Antigen Conformation Is the Scientific Breakthrough That Ended 60 Years of RSV Vaccine Development Failure.Pfizer's Abrysvo maternal RSV vaccine and GSK's Arexvy older-adult RSV vaccine represent the commercially significant vaccine launches since COVID-19, collectively generating over USD 3 billion in 2024 from the first year of commercial availability of a disease category without any approved vaccine at the start of 2023. ACIP's recommendation of either Pfizer or GSK RSV vaccine for adults 60-plus and Abrysvo specifically for maternal vaccination at 32-36 weeks gestation creates a multi-product prescribing choice unusual in vaccine markets. The older-adult RSV vaccine market competition between Pfizer and GSK requires prescriber education about clinical trial evidence, dosing schedules, and safety data differentiating two vaccines targeting the same prefusion F protein through distinct molecular designs.
Maternal Abrysvo RSV Vaccine Demonstrating 82 Percent Protection Against Severe Infant LRTD in MATISSE by Third-Trimester Placental Antibody Transfer Has Established the Maternal Immunisation Strategy for the Youngest Infants Too Young for Direct Vaccination.CDC's VISION network analysis demonstrated 75-80% effectiveness against RSV hospitalisation in adults 60-plus across the 2023-2024 RSV season with either Pfizer Abrysvo or GSK Arexvy, consistent across age subgroups including 80-plus year-olds where influenza and COVID-19 vaccine effectiveness is significantly lower. The rapid accumulation of real-world effectiveness data from US RSV surveillance networks established for COVID-19 monitoring enabled high-quality effectiveness estimation in the first commercial RSV vaccine season. Durability of RSV vaccine protection beyond the initial season is the primary outstanding clinical evidence question, and 3-year extension data from RENOIR and SILVER trials will determine whether single-dose lifetime protection or annual boosting is optimal for elderly populations.
Nirsevimab Beyfortus Single-Dose Monoclonal Antibody Providing Full RSV Season Protection Versus Five Monthly Palivizumab Injections Has Transformed Infant RSV Prophylaxis From a High-Burden Repeated Injection Regimen to a Single Administration at Birth.Moderna's mRNA-1345 Mresvia demonstrated 83.7% efficacy against RSV lower respiratory tract disease in RENEW, earning FDA approval in May 2024 as the third approved adult RSV vaccine within 15 months of the first approval and demonstrating the mRNA platform's capability to enter established vaccine markets with competitive efficacy data. The mRNA sequence update advantage for RSV vaccine is theoretical at present since RSV strains have not evolved resistance to the conserved pre-fusion F epitopes targeted by all current vaccines, but the manufacturing infrastructure established for Moderna's COVID-19 vaccine and repurposed for mRNA-1345 enables rapid sequence modification if RSV evolution warrants updated antigen design. The three-vaccine RSV adult market competition among Abrysvo, Arexvy, and Mresvia resembles the mature influenza vaccine market where clinical evidence differentiation, payer formulary placement, and commercial infrastructure determine share.
For related market intelligence, see the Vaccine Market.
8. Segmental Analysis
By product type, the recombinant protein subunit segment dominated the RSV Vaccine Market in 2025, as Pfizer's Abrysvo and GSK's Arexvy delivered the first approved adult RSV vaccines, generating the foundational commercial revenue for this newly established vaccine category.
By target, the maternal and infant segment is projected to register the highest growth rate through 2034, as Pfizer's maternal RSV vaccination programme complements monoclonal antibody prevention and adds a vaccine-mediated protection pathway for the most vulnerable early-life population.
9. Regional Analysis
Regional demand patterns across the RSV Vaccine Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the RSV Vaccine Market in 2025, accounting for approximately 42% of global revenue, attributed to the US as the primary commercial launch market for Arexvy and Abrysvo with premium pricing and the large adult-over-60 population eligible for vaccination. Moreover, maternal RSV vaccination programme adoption is advancing in the US. In addition, mRNA RSV vaccine development is centred in North American companies. Regional leadership is due to this combination of commercial launch leadership and elderly population scale.
Highest CAGR Region
Europe is projected to register the highest CAGR in the RSV Vaccine Market through 2034, driven by expanding RSV vaccination recommendations and reimbursement approvals across European countries and the large elderly population eligible for adult RSV immunisation. The region is also witnessing maternal RSV vaccination programme implementation. Moreover, national health system RSV vaccination uptake is accelerating. The combination of these demand drivers and recommendation expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The RSV Vaccine Market was valued at USD 4.85 Bn in 2025 and is projected to reach USD 22.33 Bn by 2034, growing at a CAGR of 18.5% over the 2026–2034 forecast period.
The RSV Vaccine Market is projected to grow at a CAGR of 18.5% from 2026 to 2034.
North America dominated the RSV Vaccine Market in 2025, accounting for approximately 42% of global revenue, attributed to the US as the primary commercial launch market for Arexvy and Abrysvo with premium pricing and the large adult-over-60 population eligible for vaccination.
The leading companies in the RSV Vaccine Market include Pfizer, GSK, Moderna, Sanofi, AstraZeneca, Bavarian Nordic, Johnson and Johnson, Novavax.
Prefusion f protein stabilisation by mclellan and colleagues enabling broadly neutralising antibody induction against the native rsv antigen conformation is the scientific breakthrough that ended 60 years of rsv vaccine development failure.
By product type, the recombinant protein subunit segment dominated the RSV Vaccine Market in 2025, as Pfizer's Abrysvo and GSK's Arexvy delivered the first approved adult RSV vaccines, generating the foundational commercial revenue for this newly established vaccine category.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.